相似文献
1
Converting cancer mutations into therapeutic opportunities.
EMBO Mol Med. 2009 Sep;1(6-7):297-9. doi: 10.1002/emmm.200900044.
2
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
EMBO Mol Med. 2009 Sep;1(6-7):315-22. doi: 10.1002/emmm.200900041.
3
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Oncogene. 2018 Jan 18;37(3):341-351. doi: 10.1038/onc.2017.326. Epub 2017 Sep 25.
4
Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.
Cancer Sci. 2018 Mar;109(3):821-831. doi: 10.1111/cas.13477. Epub 2018 Jan 30.
5
[Cancer therapy by PARP inhibitors].
Nihon Rinsho. 2015 Aug;73(8):1330-5.
6
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
BMC Cancer. 2017 Sep 8;17(1):638. doi: 10.1186/s12885-017-3639-0.
7
Olaparib.
Br J Clin Pharmacol. 2016 Jan;81(1):171-3. doi: 10.1111/bcp.12761. Epub 2015 Oct 24.
8
Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
J Natl Cancer Inst. 2017 Mar 1;109(3):1-13. doi: 10.1093/jnci/djw229.
9
PARP Inhibitors in Prostate Cancer.
Anticancer Res. 2021 Feb;41(2):551-556. doi: 10.21873/anticanres.14807.
10
Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
J Pathol. 2017 Mar;241(4):511-521. doi: 10.1002/path.4857. Epub 2017 Jan 23.
引用本文的文献
1
Inhibition of DNA glycosylases via small molecule purine analogs.
PLoS One. 2013 Dec 9;8(12):e81667. doi: 10.1371/journal.pone.0081667. eCollection 2013.
2
BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
PLoS One. 2012;7(1):e30042. doi: 10.1371/journal.pone.0030042. Epub 2012 Jan 11.
本文引用的文献
1
Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2.
EMBO Mol Med. 2009 Sep;1(6-7):323-37. doi: 10.1002/emmm.200900040.
2
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
EMBO Mol Med. 2009 Sep;1(6-7):315-22. doi: 10.1002/emmm.200900041.
3
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.
4
Finding and drugging the vulnerabilities of RAS-dependent cancers.
Cell. 2009 May 29;137(5):796-8. doi: 10.1016/j.cell.2009.05.011.
5
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen.
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16484-9. doi: 10.1073/pnas.0806574105. Epub 2008 Oct 23.
6
Essential role for nuclear PTEN in maintaining chromosomal integrity.
Cell. 2007 Jan 12;128(1):157-70. doi: 10.1016/j.cell.2006.11.042.
7
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
Cancer Res. 2006 Aug 15;66(16):8109-15. doi: 10.1158/0008-5472.CAN-06-0140.
8
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Nature. 2005 Apr 14;434(7035):917-21. doi: 10.1038/nature03445.
9
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Nature. 2005 Apr 14;434(7035):913-7. doi: 10.1038/nature03443.
10
Lack of PTEN sequesters CHK1 and initiates genetic instability.
Cancer Cell. 2005 Feb;7(2):193-204. doi: 10.1016/j.ccr.2005.01.009.
Zotero 插件